Company intelligence / Profile preview

Coressence

Ownership: Private
Development stage: Other

Overview

In 2011, Coressence was awarded UK government funding to conduct feasibility studies applying industrial biotechnology to the competitive production of high-value chemicals and polymers. The company’s work included exploring agricultural feedstocks, novel biocatalysts, and bioreactor technologies for sustainable alternatives to petrochemical-derived products or creation of active pharmaceutical ingredients via bio-transformations. No recent clinical results are available.

Therapeutic areas: Other
Modalities: Biocatalyst-based processSmall molecule synthesis via biotransformation
Industry: Non-Drug Biotech

Partnerships

UK Technology Strategy Board-funded consortium

Beyond the preview

Go deeper on Coressence.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coressence.

Explore the full profile